C. D. Fletcher

KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance

J. Fletcher, G. Demetri, C. Fletcher, 2007, Oncogene.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

J. Crowley, G. Demetri, R. Maki, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status.

C. Antonescu, J. Fletcher, G. Demetri, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gastrointestinal stromal tumors

Jonathan A. Fletcher, Bernadette Liegl-Atzwanger, C. D. Fletcher, 2010, Virchows Archiv.

Protein kinase C-θ regulates KIT expression and proliferation in gastrointestinal stromal tumors

J. Fletcher, G. Demetri, C. Fletcher, 2008, Oncogene.

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST).

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Problems in grading soft tissue sarcomas.

C. Fletcher, F. M. Brown, C. D. Fletcher, 2000, American journal of clinical pathology.